MeSH term
Frequency | Condition_Probility | Female | 78 | 0.0 |
Humans | 198 | 0.0 |
Pregnancy | 4 | 0.0 |
Amyloidosis/*metabolism | 5 | 45.0 |
Animals | 46 | 0.0 |
Immunoblotting | 3 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Mice | 20 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Myocardium/metabolism | 3 | 1.0 |
Serum Amyloid A Protein/metabolism | 4 | 23.0 |
Adult | 61 | 0.0 |
Aged | 39 | 0.0 |
Base Sequence | 10 | 0.0 |
Cohort Studies | 4 | 0.0 |
Comparative Study | 37 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 19 | 0.0 |
Incidence | 3 | 0.0 |
Logistic Models | 3 | 0.0 |
Male | 81 | 0.0 |
Middle Aged | 56 | 0.0 |
Molecular Sequence Data | 27 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Prospective Studies | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 103 | 0.0 |
Risk Factors | 8 | 0.0 |
Taiwan/epidemiology | 2 | 1.0 |
Amyloidosis/*complications/metabolism/pathology | 2 | 100.0 |
Serum Amyloid A Protein/*metabolism | 12 | 30.0 |
Anthropometry | 2 | 0.0 |
Child | 12 | 0.0 |
Child, Preschool | 7 | 0.0 |
Homozygote | 3 | 0.0 |
Amino Acid Sequence | 22 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 53 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Cattle | 10 | 0.0 |
Cell Line | 8 | 0.0 |
Neutrophils/*metabolism | 2 | 1.0 |
Observer Variation | 2 | 1.0 |
Reference Standards | 2 | 0.0 |
*World Health Organization | 2 | 28.0 |
In Vitro | 11 | 0.0 |
Models, Molecular | 2 | 0.0 |
Structure-Activity Relationship | 6 | 0.0 |
Amyloidosis/*etiology/pathology | 3 | 60.0 |
Diagnosis, Differential | 3 | 0.0 |
Kidney/pathology | 4 | 2.0 |
Analysis of Variance | 3 | 0.0 |
Cell Division | 4 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
*African Continental Ancestry Group | 2 | 1.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Congo Red | 3 | 20.0 |
Fatal Outcome | 3 | 0.0 |
Serum Amyloid A Protein/*analysis | 14 | 35.0 |
Amyloid/analysis | 3 | 17.0 |
Biopsy | 4 | 0.0 |
Inflammation/*complications | 2 | 16.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Adolescent | 19 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Gene Frequency | 5 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
*Polymorphism, Genetic | 8 | 0.0 |
Hydrolysis | 3 | 0.0 |
Alleles | 10 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Amyloidosis/etiology | 2 | 28.0 |
Apolipoproteins/*metabolism | 3 | 7.0 |
Amyloidosis/complications/metabolism/*pathology | 3 | 100.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Aging | 2 | 0.0 |
Body Mass Index | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 23 | 0.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Infant | 5 | 0.0 |
Protein Binding | 3 | 0.0 |
Acute Disease | 5 | 0.0 |
Disease Progression | 2 | 0.0 |
Odds Ratio | 5 | 0.0 |
Sex Factors | 2 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
Immunoenzyme Techniques | 11 | 0.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
Chronic Disease | 3 | 0.0 |
Polymorphism, Genetic | 6 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
English Abstract | 13 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Glutathione Transferase/*genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Kinetics | 6 | 0.0 |
Lipoxygenase/metabolism | 3 | 17.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Nutritional Status | 2 | 1.0 |
Cell Division/*drug effects | 3 | 1.0 |
Kidney | 2 | 0.0 |
Serum Amyloid A Protein/*genetics | 4 | 11.0 |
Time Factors | 6 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Disease Models, Animal | 5 | 0.0 |
Rats | 7 | 0.0 |
Mutation | 2 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Prognosis | 4 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Amyloidosis/metabolism/*pathology | 4 | 57.0 |
Terminology | 2 | 1.0 |
Serum Amyloid A Protein/analysis | 7 | 18.0 |
Antibody Specificity | 3 | 0.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Fatty Acids, Omega-3/metabolism | 3 | 60.0 |
Fatty Acids, Omega-6 | 3 | 23.0 |
Haplotypes | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Silver Nitrate/administration & dosage | 2 | 66.0 |
Myocardium/pathology | 2 | 2.0 |
Species Specificity | 4 | 0.0 |
Swine | 2 | 0.0 |
*Homozygote | 2 | 1.0 |
Erythrocytes/*metabolism | 4 | 1.0 |
*Basal Metabolism | 2 | 13.0 |
Energy Intake | 2 | 1.0 |
Amyloid/*analysis | 13 | 37.0 |
Retrospective Studies | 5 | 0.0 |
*Infant Food | 3 | 8.0 |
Infant, Newborn | 5 | 0.0 |
Binding Sites | 6 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Melitten/pharmacology | 2 | 15.0 |
Phospholipases A/metabolism | 2 | 3.0 |
Cross Reactions | 2 | 0.0 |
Isomerism | 2 | 0.0 |
Amyloid/*metabolism | 4 | 7.0 |
Amino Acids/*blood | 2 | 10.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Transfection | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Osmolar Concentration | 3 | 0.0 |
Binding, Competitive | 4 | 0.0 |
Age Factors | 2 | 0.0 |
Probability | 2 | 0.0 |
Serum Amyloid P-Component/analysis | 2 | 50.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Amyloidosis/*pathology | 4 | 50.0 |
Microscopy, Electron | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Western | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Immunosorbent Techniques | 2 | 0.0 |
Molecular Weight | 11 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Prealbumin/analysis | 2 | 8.0 |
beta 2-Microglobulin/analysis | 2 | 1.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Rabbits | 3 | 0.0 |
Amyloidosis/*diagnosis/metabolism/pathology | 2 | 100.0 |
*Signal Transduction | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Plasmin/metabolism | 2 | 2.0 |
Trypsin/metabolism | 3 | 2.0 |
Collagen/*metabolism | 2 | 1.0 |
Amyloid/*analysis/immunology | 2 | 100.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Liver/analysis | 2 | 11.0 |
Drug Evaluation | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Receptors, Platelet-Derived Growth Factor | 2 | 6.0 |
Kidney/analysis | 2 | 13.0 |
*Serum Amyloid A Protein | 3 | 100.0 |
Arachidonic Acid | 8 | 12.0 |
Dinoprostone | 3 | 4.0 |
Tissue Distribution | 2 | 0.0 |
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 4 | 25.0 |
Arachidonic Acids/*pharmacology | 3 | 16.0 |
Platelet Aggregation/*drug effects | 3 | 2.0 |
Prostaglandin Endoperoxides, Synthetic/*pharmacology | 3 | 100.0 |
Apolipoprotein A-I | 2 | 1.0 |
Rats, Inbred Strains | 2 | 0.0 |
Chromosome Disorders | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Electrolytes/*blood | 2 | 50.0 |
Syndrome | 2 | 0.0 |
Amyloid/*blood | 3 | 21.0 |
Serum Amyloid A Protein/*blood | 3 | 60.0 |
Aspirin/*pharmacology | 2 | 4.0 |
Blood Platelets/drug effects/*physiology/ultrastructure | 2 | 33.0 |
Collagen/*pharmacology | 2 | 7.0 |
Thrombin/physiology | 2 | 5.0 |
Thromboxanes/blood | 2 | 66.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
*Chromosomes, Human, 21-22 and Y | 2 | 11.0 |
Serum Amyloid P-Component | 2 | 18.0 |
Arthritis, Rheumatoid/blood | 2 | 7.0 |
Lupus Erythematosus, Systemic/blood | 2 | 7.0 |
*Amyloid | 2 | 50.0 |
Chromatography, Gel | 3 | 0.0 |
